Highlights Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Real-time Estimate Cboe Europe Other stock markets 05:48:11 2024-04-29 am EDT			5-day change	1st Jan Change
104.8 ^SEK	+1.01%		+4.59%	-17.47%

Apr. 25	European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	MT
Apr. 24	Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading	Apr. 25	MT
Calliditas Therapeutics AB Announces Positive NefIgArd Open Label Extension Results	Apr. 24	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	CI
Calliditas Therapeutics AB Presents Additional Data Analyses from the Phase 3 NeflgArd Trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024	Apr. 18	CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading	Apr. 15	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading	Apr. 09	MT
Calliditas Therapeutics AB to Present Nefecon Data At the ISN World Congress of Nephrology in Buenos Aires	Apr. 08	CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Mar. 25	MT
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®	Mar. 11	CI
Calliditas Therapeutics Says Kidney Disease Drug Granted Seven-Year Exclusivity Period by FDA	Mar. 06	MT
Calliditas Therapeutics AB Announces an Additional Seven Year Orphan Drug Exclusivity Period for TARPEYO	Mar. 06	CI
Travere drug for rare kidney condition recommended for EU approval	Feb. 23	RE
Calliditas Therapeutics AB Provides Revenue Guidance for the Year Ending December 31, 2024	Feb. 21	CI
Calliditas Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 21	CI
Calliditas Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Highlights

Filters